EQL Pharma AB (publ)

OM:EQL 株式レポート

時価総額:SEK 1.7b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

EQL Pharma 過去の業績

過去 基準チェック /16

EQL Pharmaは、平均年間41%の収益成長を遂げていますが、 Healthcare業界の収益は、年間 成長しています。収益は、平均年間31.5% 28.7%収益成長率で 成長しています。 EQL Pharmaの自己資本利益率は12.8%であり、純利益率は8.6%です。

主要情報

41.0%

収益成長率

41.4%

EPS成長率

Healthcare 業界の成長8.1%
収益成長率28.7%
株主資本利益率12.8%
ネット・マージン8.6%
次回の業績アップデート08 Aug 2024

最近の業績更新

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

収支内訳

EQL Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

OM:EQL 収益、費用、利益 ( )SEK Millions
日付収益収益G+A経費研究開発費
31 Mar 24264237112
31 Dec 23246226814
30 Sep 23256286414
30 Jun 23270306314
31 Mar 23260316015
31 Dec 22403335914
30 Sep 22440395611
30 Jun 2241936519
31 Mar 2241032489
31 Dec 21233194110
30 Sep 2114543411
30 Jun 2111723112
31 Mar 21179102812
31 Dec 2017217322
30 Sep 2016316322
30 Jun 2015714322
31 Mar 20723300
31 Dec 19682245
30 Sep 1958-2253
30 Jun 1954-2252
31 Mar 1950-2250
31 Dec 1843-2210
30 Sep 18410200
30 Jun 18350180
31 Mar 1832-1170
31 Dec 17301160
30 Sep 17300150
30 Jun 17260150
31 Mar 17240140
31 Dec 16314150
30 Sep 16295140
30 Jun 16346140
31 Mar 16357140
31 Dec 15294130
30 Sep 15261130
30 Jun 1521-2130
31 Mar 1519-5130
31 Dec 1418-9130
30 Sep 1419-11130
30 Jun 1419-12120
31 Mar 1420-11110
31 Dec 1322-8100

質の高い収益: EQL 非現金収入 のレベルが高いです。

利益率の向上: EQLの現在の純利益率 (8.6%)は、昨年(11.9%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: EQL過去 5 年間で収益を上げており、収益は年間41%増加しています。

成長の加速: EQLは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: EQLは過去 1 年間で収益成長率がマイナス ( -26.6% ) となったため、 Healthcare業界平均 ( -8.4% ) と比較することが困難です。


株主資本利益率

高いROE: EQLの 自己資本利益率 ( 12.8% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘